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expansion is slower than for 3i-treated
wild-type cells. Despite this finding, sev-
eral questions remain with regard to
WNT signaling. What are the downstream
consequences of elevated (approximately
3-fold) WNT signaling? It is noteworthy
that recombinant WNT3A is not function-
ally equivalent to CHIR99021, and endog-
enous expression of Wnt3 and Wnt8 is
low in wild-type ESCs (Lindsley et al.,
2006). Thus, GSK3 inhibition might result
in downstream transcriptional outputs
that are LEF/TCF-independent. This pos-
sibility could be further examined in ESCs
in which the b-catenin pool is artificially
stabilized. The authors posit that lowered
GSK3 levels globally impact the ‘‘energy
level’’ within a given stem cell, accommo-
dating the dramatic loss of activated ERK
and its role in basic cellular processes.
Whither LIF? Since its identification two
decades ago, LIF has been considered
a guardian of ESC fate, with most models
emphasizing the requirement for LIF-me-
diated activation of STAT3 to maintain
self-renewal and pluripotency (Chambers
and Smith, 2004). For example, it is im-
possible to isolate ESC lines that overex-
press a dominant-interfering STAT3 mu-
tant (Niwa et al., 1998). Ying et al.,
however, succeeded in isolating Stat3-
deficient ESC lines using their defined 3i
medium. When exposed to LIF and se-
rum, these cells expectedly fail to activate
the STAT3 target gene Socs3 and rapidly
differentiate. These findings demonstrate
unequivocally that LIF signaling is entirely
dispensable. With its elimination as a nec-
essary extrinsic signal for self-renewal,
mouse ESCs can now be studied in their
experimentally induced ‘‘ground state,’’
where their basic, intrinsic mechanisms
of self-duplication and pluripotency are
revealed in a neutralized tissue-culture
environment and await precise character-
ization.
One practical outcome of this work is
the possibility that mouse ESC culture
and derivation platforms can be simplified
and standardized with 3i medium. This
would certainly be welcomed as a cost-
effective solution to the considerable ex-
penses of fetal bovine serum and re-
combinant LIF. Lastly, the inevitable
question will arise: What about human
ESCs? It is important to emphasize that
human and mouse ESCs are nonequiva-
lent with regard to their culture require-
ments, with human ESCs mostly depen-
dent upon extrinsic FGF and Activin/
Nodal signaling for their propagation (Val-
lier et al., 2005). Although 3i will likely trig-
ger rapid differentiation of human ESCs,
the strategy developed by Ying et al.
certainly emboldens current screening
efforts aimed at identifying small mole-
cules that will equally sustain human
ESC self-renewal and, importantly, facili-
tate scale-up for the production of
clinically relevant cell types.
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Ex vivo hematopoiesis from embryonic sources offers exciting promises in basic research and medicine. In
this issue of Cell Stem Cell, Ledran et al. (2008) describe human embryonic stem cell (hESC)-derived hema-
topoiesis, while Taoudi et al. (2008) define the origin of definitive hematopoietic stem cells (HSCs) from the
mouse aorta-gonad-mesonephros (AGM) region.While regenerative medicine in the form of
HSC transplantation has been used to
successfully treat various disorders, sig-
nificant limitations remain. Understanding
hematopoietic ontogeny and developing
efficient methods for ex vivo derivation
of hematopoietic cells will significantly
facilitate existing and novel therapeutic
strategies. In this issue of Cell Stem Cell,8 Cell Stem Cell 3, July 2008 ª2008 Elsevier Inc.
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Previewstwo groups have reported ex vivo deriva-
tion of HSCs, one from hESCs (Ledran
et al., 2008) and the other from mouse
AGM (Taoudi et al., 2008).
As ESCs possess the potential to gen-
erate any of the myriad cells in an organ-
ism, their use as an alternative hema-
topoietic cell source has been under
intensive investigation. A critical role for
the Cdx-Hox pathway has been estab-
lished in murine ESC-derived hematopoi-
esis, and BMP-4 signaling is similarly re-
quired for the parallel process using
hESCs (reviewed in McKinney Freeman
and Daley, 2007). Indeed, long-term
reconstituting serially transplantable
hESC-derived HSCs were reported by
Kaufman and colleagues (Tian et al.,
2006), albeit at low frequencies. The deri-
vation of specific lineages from ESCs has
also been a long-standing interest. Fully
functional T cells from mouse ESCs, and
erythrocytes and platelets from hESCs,
have been derived (McKinney-Freeman
and Daley, 2007; Takayama et al., 2008),
bringing the possibility of a readily avail-
able source of cells for immunotherapy
and transfusion therapy closer to reality.
In this issue of Cell Stem Cell, Ledran
et al. (2008) demonstrated the role of
TGFb1/TGFb3 in the efficient induction
of human HSCs from ESCs by using pri-
mary and immortalized AGM or fetal liver
stromal cells. The hematopoietic induc-
tion capacity of TGFb1 and TGFb3 was
significantly more efficient relative to
other cytokines, chemokines, and other
TGF family members tested and was spe-
cifically inhibited by neutralizing anti-
bodies against the two factors. It is of par-
ticular interest that these factors induced
hematopoietic development at similar ef-
ficiencies with or without stromal cell con-
tact. These findings partially address the
long-standing question of whether ESC-
derived hematopoiesis requires signaling
through adhesion molecules or humoral
factors derived from stromal elements.
The definitive in vivo characterization of
ESC-derived humanHSCs demonstrating
long-term engraftment, self-renewal ca-
pacity through serial repopulation, and
multilineage reconstitution has been chal-
lenging. The NOD/SCID repopulation of
ESC-derived human HSCs has yielded
significantly lower levels of engraftment
than cord blood-derived HSCs injected
intravenously or intrafemorally at similar
graft doses. Whether this reflects a true
difference in HSC function or is due to
the inherent limitations of the SCID
repopulating assay in supporting human
hematopoiesis remains unclear. Given
that the depletion of recipient natural killer
(NK) cell activity improves engraftment, it
appears that recipient innate immunity
plays at least a partial role (Tian et al.,
2006). NOD/SCID/IL2rg/ recipients,
used by Ledran et al. (2008), exhibit signif-
icantly higher levels of long-termmultiline-
age human immunohematopoietic repo-
pulation compared with NK-competent
NOD/SCID recipients. Further evaluations
of in vivo differentiation and functional
analysis of hematopoietic lineages will be
crucial to complement the engraftment
analyses reported in this study.
Mammalian hematopoietic ontogeny,
characterized by the sequential migration
of the site of blood cell production, can be
traced back to the ventral mesoderm,
subsequently shifting from the primitive
endoderm-derived yolk sac (YS) blood
islands, the AGM region surrounding the
dorsal aorta and the placenta, to the fetal
liver during mid-late gestation, and finally
to the bone marrow as the site of adult
hematopoiesis. Both intrinsic properties
of HSCs at each developmental stage
and the extrinsic differences in the micro-
environmental niche likely contribute to
the distinct and evolving nature of HSCs
at each site. While the importance of
AGM as the source of HSCs in the embryo
has beenwell-established, recentwork by
Nishikawa and colleagues (Samokhvalov
et al., 2007) suggests that HSC formation
also occurs in YS. To date, there is no
clear consensus as to the role of YS in
definitive hematopoiesis and whether
definitive HSCs develop independently
in multiple sites or YS-derived HSCs
migrate to the AGM through embryonic
circulation.
The study by Taoudi et al. (2008) dis-
sects the hematopoietic population within
the mouse AGM according to their prolif-
erative history and defines their functional
properties through cell-cycle analysis,
in vitro colony formation, and in vivo re-
population assays. In this study, IL-3,
thought to play a key role in the initia-
tion/expansion of definitive HSCs from
AGM (Robin et al., 2006), was used in
addition to SCF/Flt3L for the generation
of HSCs with multilineage differentiation
and self-renewal capacities from ex vivo
reaggregated AGM organoid. Interest-
ingly, during the time period in which the
number of HSCs in the AGM compart-
ment expand rapidly, the AGM-HSC cells
were relatively quiescent (in G0/G1), sug-
gesting that the proliferation of ‘‘pre-
HSCs’’ leads to HSC expansion. These
pre-HSCs were found exclusively within
the CD45+VE-cadherin+ population, pre-
viously reported to contain early HSCs
with dual hematoendothelial lineage po-
tential. The majority of CD45+VE-cad-
herin+ cells were found integrated into
the dorsal aorta endothelium as intra-
aortic clusters, raising an intriguing possi-
bility that the developing aortic endothe-
lium containing pre-HSCs represents the
‘‘hemogenic endothelium.’’ In compari-
son, in the human AGM, Simmons and
colleagues have recently reported that
clusters of CD34+primitive hematopoietic
cells at the intravascular aspect of the
ventral aortic endothelium are BB9+ (rec-
ognizing angiotensin-converting enzyme)
and speculate that these cells may beme-
sodermal precursors with hematoangio-
genic potential (Jokubaitis et al., 2008).
The two reports in this issue of Cell
Stem Cell raise key questions regarding
hematopoiesis at different developmental
stages. One is whether the induction of
hematopoiesis from ESCs necessarily
leads to the formation of functionally prim-
itive hematopoietic cells. Indeed, ery-
throid cells derived from hESCs exhibit
primitive erythroid characteristics (no
enucleation, the presence of embryonic
and fetal globins, and the lack of b-glo-
bin), as has been reported previously
(Chang et al., 2006), which also appears
to be the case in the current Ledran study.
However, it remains possible that these
findings are the artifact of current induc-
tion techniques. Another related question
is whether ESC-derived HSCs are func-
tionally comparable to HSCs derived
from the AGM and later stages of devel-
opment and what role(s) is played by the
distinct niches and possibly distinct ori-
gins of HSCs at each stage/site. The find-
ing by Taoudi et al. that the AGM-derived
HSCs are CD34 and thus appear to skip
the CD34+ stage observed in fetal liver
implies a parallel, plastic, and cooperative
aspect of developmental hematopoiesis
and suggests that the distinct niches
may play a crucial role. To begin to ad-
dress these questions, careful in situ cell
fate tracing of prenatal hematopoietic
development must be conducted inCell Stem Cell 3, July 2008 ª2008 Elsevier Inc. 9
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parisons of derived cells in a robust trans-
plantation setting. The elaboration of the
molecular mechanisms involved in the
specification of HSCs and lineage differ-
entiation in their distinct niches must
also be pursued. The recent induction of
ESC-like pluripotent cells from mouse
and human (reviewed in Jaenisch and
Young, 2008) and methodologies such
as ex vivo reaggregation/organoid forma-
tion provide exciting new prospects for
both targeted genetic manipulations and
global analyses at the genome, epige-
nome, and protein levels.
REFERENCES
Chang, K.H., Nelson, A.M., Cao, H., Wang, L., Na-
kamoto, B., Ware, C.B., and Papayannopoulou, T.
(2006). Blood 108, 1515–1523.
Jaenisch, R., and Young, R. (2008). Cell 132, 567–
582.
Jokubaitis, V.J., Sinka, L., Driessen, R., Whitty, G.,
Haylock, D.N., Bertoncello, I., Smith, I., Pe´ault, B.,
Tavian, M., and Simmons, P.J. (2008). Blood 111,
4055–4063.
Ledran, M.H., Krassowska, A., Armstrong, L.,
Dimmick, I., Renstro¨m, J., Yung, S., Santibanez-
Coref, M., Dzierzak, E., Stojkovic, M., Oosten-
dorp, R., et al. (2008). Cell Stem Cell 3, this issue,
85–98.
McKinney-Freeman, S.L., and Daley, Q. (2007).
Curr. Opin. Hematol. 14, 343–347.
Robin, C., Ottersbach, K., Durand, C., Peeters, M.,
Vanes, L., Tybulewicz, V., and Dzierzak, E. (2006).
Dev. Cell 11, 171–180.
Samokhvalov, I.M., Samokhvalova, N.I., and Nish-
ikawa, S. (2007). Nature 446, 1056–1061.
Takayama, N., Nishikii, H., Usui, J., Tsukui, H., Sa-
waguchi, A., Hiroyama, T., Eto, K., and Nakauchi,
H. (2008). Blood 111, 5298–5306.
Taoudi, S., Gonneau, C., Moore, K., Sheridan, J.,
Blackburn, C., Taylor, E., and Medvinsky, A.
(2008). Cell Stem Cell 3, this issue, 99–108.
Tian, X., Woll, P.S., Morris, J.K., Linehan, J.L., and
Kaufman, D.S. (2006). Stem Cells 24, 1370–1380.10 Cell Stem Cell 3, July 2008 ª2008 Elsevier Inc.
